A retrospective, matched case-control study of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol

Ming-Jer Chen1,2*, Yu-Chiao Yi1,2†, Hwa-Fen Guu1, Ya-Fang Chen1, Hsiao-Fan Kung1, Jui-Chun Chang1, Shih-Ting Chuan1 and Li-Yu Chen1

1Department of Obstetrics and Gynecology and Women’s Health, Taichung Veterans General Hospital, Taichung, Taiwan, 2School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

Background: The role of luteinizing hormone (LH) in controlled ovarian hyperstimulation (COH) requires more evidence for its efficacy. Several studies compared recombinant human LH (r-hLH) or human menopausal gonadotropin (hMG) in combination with recombinant human follicle-stimulating hormone (r-hFSH) but lack the results with GnRH-antagonist protocol and in Asians.

Methods: This is a retrospective, single-center study inspecting women receiving GnRH antagonist protocol and r-hFSH+hMG or r-hFSH+r-hLH regimen for over five days for COH in the in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycle in Taiwan from 2013 to 2018. The outcomes of IVF/ICSI cycles were analyzed after propensity score matching between the two groups. A subgroup analysis was conducted in cycles in which women underwent their first embryo transfer (ET), including fresh ET and frozen ET (FET).

Results: With a total of 503 cycles, the results revealed that the r-hFSH+r-hLH group performed better in terms of numbers of oocytes retrieved (r-hFSH+hMG vs. r-hFSH+r-hLH, 11.7 vs. 13.7, p=0.014), mature oocytes (8.7 vs. 10.9, p=0.001), and fertilized oocytes (8.3 vs. 9.8, p=0.022), while other outcomes were comparable. The analysis of first ET cycles also showed similar trends. Although the implantation rate (39% vs. 43%, p=0.37), pregnancy rate (52% vs. 53%, p=0.90), and live birth rate (39% vs. 45%, p=0.19) were not significantly different, the miscarriage rate was higher in the r-hFSH+hMG group than the r-hFSH+r-hLH group (26% vs. 15%, p=0.05) in first ET cycles. The cumulative live birth rate was significantly higher in the r-hFSH+r-hLH group (53% vs.
No significant difference in rates of ovarian hyperstimulation syndrome (OHSS) was observed.

**Conclusion:** The results support the hypothesis that the treatment of r-hLH+r-hFSH improves COH clinical outcomes in the IVF/ICSI cycle.

**KEYWORDS**
controlled ovarian hyperstimulation, recombinant FSH, recombinant LH, human menopausal gonadotrophin (hMG), pregnancy

**Introduction**

Controlled ovarian hyperstimulation (COH) in the *in vitro* fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycle is dependent on the regulation of gonadotropin-releasing hormone (GnRH) and gonadotropin treatment. Among the gonadotropins, follicle-stimulating hormone (FSH) is necessary to stimulate follicle growth in the ovaries, while the role of luteinizing hormone (LH) remains debatable. A meta-analysis suggests no significant difference between FSH+LH and FSH alone with GnRH-antagonist protocol in COH (1), but the supplement of LH appears to be beneficial in certain subgroups of women in more recent studies (2–4). Notably, LH supplement was shown to lead to a higher cumulative live birth rate (cLBR) than FSH alone in poor ovarian responders in a large retrospective study containing more than 9,000 cycles (5). In clinical practice, human menopausal gonadotropin (hMG) with both FSH and LH bioactivity is often applied for COH. Even though highly purified hMG suffers from impurity and potential contaminants due to being extracted from human urine (6), it is reported that the effects of hMG and recombinant human follicle-stimulating hormone (r-hFSH) are comparable in COH (7, 8).

Several studies compared the use of hMG versus r-hFSH plus recombinant human luteinizing hormone (r-hLH) but with discrepant results. Overall, there was no significant difference in pregnancy rates observed in the total population (9–11). Two studies revealed that the groups receiving r-hFSH+r-hLH had a higher pregnancy rate than hMG in patients with hypogonadotropic hypogonadism or with poor ovarian reserve (12, 13). Another study demonstrated that the pregnancy rate was significantly higher in the group of r-hFSH+r-hLH when the oocyte yield was high (9). As for the safety concerns, two reports indicated a higher risk of ovarian hyperstimulation syndrome (OHSS) when patients are treated with r-hFSH+r-hLH than with hMG (10, 11).

Other research has been conducted to compare the effects of r-hLH and hMG in the presence of FSH. A retrospective study found that the group of r-hFSH+r-hLH had more oocytes retrieved, more embryos, and a higher pregnancy rate than that of r-hFSH+hMG (14). Similar outcomes were demonstrated by a randomized controlled trial: a higher number of mature oocytes and higher pregnancy rates were observed in the group supplementing r-hLH than its hMG counterpart (15). One particular three-group study compared the efficacy of r-hFSH+r-hLH, r-hFSH+hMG, and hMG alone (16). Among the three groups, the r-hFSH+r-hLH one performed best in clinical pregnancy rate and implantation rate. Overall, previous studies suggested that r-hLH resulted in better outcomes than hMG when applied in addition to FSH.

The aforementioned studies mostly focused on Western populations, and none of them have provided evidence of the treatment outcomes of r-hFSH+hMG in Asians. Besides, only a few of them applied GnRH-antagonist protocol, which was reported to have lower risks of OHSS without significant difference in clinical pregnancy rate and live birth rate comparing to GnRH-agonist protocol for COH (17, 18). A meta-analysis of subgroup analyses stratified by GnRH-agonist or antagonist protocols found evidence that the outcomes of assisted reproductive technology (ART) may differ between protocol types (19). In consequence, we conducted a real-world study to evaluate the efficacy of r-hFSH+r-hLH versus r-hFSH+hMG in COH with GnRH-antagonist protocol for the IVF/ICSI cycle in Taiwanese patients managed in our center.

**Methods**

**Study design**

The data were collected from women who received COH regimens between 2013 and 2018 in Taichung Veterans General Hospital (TCVGH, Taiwan). The selection criteria included those who received GnRH-antagonist protocol and were treated with the r-hFSH+r-hLH or r-hFSH+hMG regimen for at least 5 days before further procedures. The flowchart of the
study design is presented in Figure 1. A total of 1,064 cycles in Group 1 (r-hFSH+hMG) and 197 cycles in Group 2 (r-hFSH+r-hLH) meeting the criteria were included. Propensity score matching was applied to select matched subjects with balanced age, anti-mullerian hormone (AMH) level, and oocyte retrieval date across the two groups with a ratio of 2:1. After matching, 311 cycles in Group 1 and 192 cycles in Group 2 were analyzed. Since the best embryos were transferred at the first embryo transfer (ET), the cycles in which patients received their first fresh ET or frozen ET (FET) procedure were further subjected to subgroup analysis, including 256 cycles in Group 1 and 166 cycles in Group 2. The outcomes were estradiol (E2) levels on the human chorionic gonadotropin (hCG)-administered day, endometrial thickness on the hCG-administered day, number of oocytes retrieved, number of mature oocytes, number of fertilized oocytes, number of grade 1 to 2 embryos on cycle day 3, number of embryos transferred, number of successful implantations, implantation rate, pregnancy rate, live birth rate, miscarriage rate, the rate of OHSS, and cLBR. The study was approved by the institutional review board of TCVGH (Permission number: CE21401B).

**Ovarian stimulation and oocyte retrieval**

Baseline levels of serum FSH and LH were tested on cycle day 2 or 3. In Group 1, the COH was executed through r-hFSH (Gonal-F, 75–300 IU per day) and hMG (Menopur, 75–300 IU FSH and 75–300 IU LH per day), while in Group 2, patients received r-hFSH and r-hLH (Pergoveris, 150–300 IU FSH and 75–150 IU LH per day) either with or without the supplement of r-hFSH (Gonal-F, 75–300 IU per day). GnRH antagonist (Cetrotide, 0.25 mg/day) was administered for pituitary gland downregulation with a flexible protocol starting when the dominant follicle developed to 12–14 mm in diameter until the day of hCG trigger. When at least 3 dominant follicles were larger than 17 mm in average diameter, recombinant hCG (Ovidrel, 250 µg) and/or GnRH agonist (Decapeptyl, 0.2 mg) was delivered to trigger ultimate oocyte maturation. The dual trigger with Ovidrel and Decapeptyl has been routinely performed since 2014 in our center, except for the patients with high risks of OHSS, who were triggered with GnRH agonist only and whose fresh cycle were canceled. Oocyte retrieval was conducted 35–37 hours after the trigger.

**Fertilization, embryo transfer, and pregnancy assessment**

The oocytes were inseminated using IVF or ICSI. The embryos were graded according to the morphological classification by Veeck’s criteria (20). One to four fresh or frozen embryos were transferred per cycle. Luteal support was given from the day after oocyte retrieval with a combination of oral Duphaston 10 mg BID and transvaginal 8% Crinone gel 90 mg QD until the day of hCG check-up and continued to 8 gestational weeks (GWs) in fresh ET cycles. In FET cycles, the endometrial preparations were programmed either by hormone

---

**FIGURE 1**

Flowchart of the study design.
replacement cycles or modified natural cycles, depending on the individual conditions of each patient. Details of the endometrium priming and luteal phase support have been reported earlier (21). Pregnancy was confirmed with the positive β-hCG serum level tested 14 days after oocyte retrieval. Implantation was defined as the visible gestational sacs in 6 GWs. Live birth was defined as the delivery of a live baby after at least 24 GWs. Cumulative live birth was defined as the occurrence of live birth from one oocyte retrieval cycle until all the available embryos from that cycle were used. The second live birth from the same oocyte retrieval cycle would not be counted again.

Statistics

Greedy nearest neighbor matching was applied to calculate the propensity score matching in baseline parameters in a ratio of 2:1 for Group 1 and 2. Categorical items were described using percentages and frequencies, whereas continuous characteristics were assessed using descriptive statistics (number of subjects, mean, standard deviation). The parameters were compared using two-sample t-test for continuous variables, and the comparison between categorical variables was conducted with chi-square test. Normality tests were not performed for continuous data due to the assumption of a sufficient sample size (n=503). Significance was defined as P-value <0.05. All analyses were processed with SAS® version 9.4 or later (SAS Institute Inc, Cary, NC, USA).

Results

The patients in Group 1 or Group 2 were treated with r-hFSH+hMG or r-hFSH+r-hLH during COH, respectively. The baseline characteristics of the total analyzed cycles are shown in Table 1. The mean ages of the patients were 36.05 and 35.48 years, with the body mass index (BMI) around 22.5 and the average anti-mullerian hormone (AMH) level 3.5 and 3.8 ng/ml. The age, BMI, and AMH levels in both groups were comparable after propensity score matching (p>0.05). The analysis showed that the total dose of gonadotropins and induce days were less in Group 2 (Table S1). The basal serum level of LH was higher in Group 2 (3.9 vs. 4.7 IU/L, p=0.032), and the trigger types between the two groups showed a significant difference (p=0.007). The outcomes of the first ET cycles are presented in Table 3. Among the outcomes before the ET, the E2 level on the trigger day (2633 vs. 3079 pg/ml, p=0.036), the numbers of oocytes retrieved, mature oocytes, and fertilized oocytes were superior in Group 2. The endometrial thickness and the number of grade 1 to 2 embryos on day 3 were not significantly different (p=0.665 and p=0.302, respectively). As for the outcomes after the ET, the implantation rate (39% vs. 43%, p=0.37), the pregnancy rate (52.3% vs. 53.0%, p=0.893), and the live birth rate (38.7% vs. 45.2%, p=0.185) were higher in Group 2 than in Group 1 even though not significantly different, and the miscarriage rate was significantly lower in Group 2 (26.1% vs. 14.8%, p=0.045). The risks of OHSS were comparable (p=0.848). Based on the IVF/ICSI and ET results, the r-hFSH+r-hLH group achieved better performance not only on some of the parameters before the ET but also on the miscarriage rate in the first ET cycles.

The cLBR of the cycles included in the analysis is shown in Figure 2. There were 138 cycles out of 259 achieved live births in Group 1 (cLBR = 53.3%), and 107 out of 166 in Group 2 (cLBR = 64.5%). The cLBR was significantly higher in the r-hFSH+r-hLH group than in the r-hFSH+hMG group (p=0.023).

To avoid potential bias caused by the fresh or frozen ET procedures, we divided the subgroups of the first ET cycles into fresh ET and FET groups. The baseline characteristics and outcomes are presented in Tables S2, S3 and 4. In the fresh ET subgroup, there were 123 cycles in Group 1 and 71 cycles in Group 2. Most of the baseline characteristics were not significantly different except the total FSH dose (Group 1 vs. Group 2, 3226 vs. 2532, p<0.001) (Table S2). The numbers of oocytes retrieved, mature oocytes, fertilized oocytes, and grade 1–2 embryos on day 3 were higher in Group 2 (Table 4). The observation agreed to the results of total cycles or the first ET cycles although lack statistical significance. In the FET subgroup, 133 cycles in Group 1 and 95 cycles in Group 2 were included.
### TABLE 1 Baseline characteristics of total stimulation cycles after matching.

|                      | GROUP 1. r-hFSH + hMG | GROUP 2. r-hFSH + r-hLH | P-value |
|----------------------|------------------------|-------------------------|---------|
| **Stimulation cycle** | n=311                  | n=192                   |         |
| Age (year)           | 36.05 ± 3.56           | 35.48 ± 3.90            | 0.099   |
| BMI (kg/m²)          | 22.48 ± 3.51           | 22.30 ± 3.15            | 0.562   |
| AMH (ng/mL)          | 3.53 ± 3.49            | 3.77 ± 3.51             | 0.448   |
| Infertility history  |                        |                         | 0.801   |
| Primary              | 186 (59.81%)           | 117 (60.94%)            |         |
| Secondary            | 125 (40.19%)           | 75 (39.06%)             |         |
| Causes of infertility|                        |                         | 0.343   |
| Uterine factor       | 89 (28.62%)            | 40 (20.83%)             |         |
| Ovarian factor       | 81 (26.05%)            | 47 (24.48%)             |         |
| Tubal factor         | 29 (9.32%)             | 24 (12.50%)             |         |
| Male factor          | 26 (8.36%)             | 22 (11.46%)             |         |
| Mix factor           | 23 (7.40%)             | 16 (8.33%)              |         |
| Others               | 63 (20.26%)            | 43 (22.40%)             |         |
| Basal FSH (mIU/mL)   | 7.13 ± 3.16            | 7.35 ± 3.67             | 0.485   |
| Basal LH (mIU/mL)    | 3.88 ± 2.06            | 4.58 ± 4.19             | 0.034*  |
| Total FSH dose (IU)  | 3362.45 ± 1072.79      | 2602.15 ± 930.26        | <0.001* |
| Total LH dose (IU)   | 1152.01 ± 608.85       | 947.66 ± 510.60         | <0.001* |
| FSH/LH dose ratio    | 4.12 ± 4.18            | 4.05 ± 3.85             | 0.843   |
| Induce days          | 10.22 ± 1.83           | 9.80 ± 1.31             | 0.003*  |
| Oral agents (used) a | 5 (1.61%)              | 5 (2.60%)               | 0.437   |
| Growth hormone (used)| 13 (4.18%)             | 6 (3.13%)               | 0.547   |
| Trigger type *       | 272 (87.46%)           | 153 (79.69%)            |         |
| GnRH-agonist b       | 17 (5.47%)             | 27 (14.06%)             |         |
| r-hCG c              | 15 (4.82%)             | 12 (6.25%)              |         |
| Others               | 7 (2.25%)              | 0 (0.00%)               |         |
| Procedure $          | 203 (65.27%)           | 117 (60.94%)            | 0.411   |
| IVF d                |                        |                         |         |
| ICSI e               | 88 (28.30%)            | 56 (29.17%)             |         |
| IVF+ICSI             | 14 (4.50%)             | 11 (5.73%)              |         |
| TESE-ICSI f          | 6 (1.93%)              | 8 (4.17%)               |         |

*Statistical significance. Values are presented in mean ± standard deviation or number (percentage).

### TABLE 2 Outcomes of total stimulation cycles after matching.

|                      | GROUP 1. r-hFSH + hMG | GROUP 2. r-hFSH + r-hLH | P-value |
|----------------------|------------------------|-------------------------|---------|
| **Stimulation cycle** | n=311                  | n=192                   |         |
| E2 level on the trigger day (pg/mL) | 2467.92 ± 1730.82     | 2908.87 ± 2265.30       | 0.022*  |
| Endometrial thickness (mm)     | 11.18 ± 2.76           | 11.09 ± 2.58            | 0.722   |
| No. of oocytes retrieved      | 11.65 ± 8.78           | 13.69 ± 9.43            | 0.014*  |
| No. of mature oocytes         | 8.71 ± 6.97            | 10.92 ± 7.88            | 0.001*  |
| No. of fertilized oocytes     | 8.25 ± 7.05            | 9.81 ± 7.86             | 0.022*  |
| No. of Grade 1-2 embryos on Day 3 | 2.74 ± 3.27            | 3.06 ± 3.37             | 0.293   |
| Moderate or severe OHSS       | 5 (1.61%)              | 3 (1.56%)               | 0.969   |

*Statistical significance. Values are presented in mean ± standard deviation or number (percentage).
The total FSH dose, total LH dose, and induce days were significantly lower in Group 2 (Table S3). The number of mature oocytes was higher in Group 2 (15.9 vs. 18.0, p=0.007), and the numbers of oocytes retrieved, fertilized oocytes and grade 1–2 embryos on day 3 showed a similar trend with the fresh ET subgroup (Table 5). Overall, the patterns of the fresh ET or FET subgroup analyses were consistent with those of total cycles or the first ET cycles.

**Discussion**

The present study aimed to investigate the clinical outcomes of r-hFSH+hMG versus r-hFSH+r-hLH during COH in women receiving antagonist protocol. Both r-hFSH+ hMG and r-hFSH+r-hLH groups achieved similar results in endometrial thickness, embryo development, and implantation rate in the IVF/ICSI cycle. Nevertheless, the r-hFSH+r-hLH regimen performed significantly better in terms of E2 level, oocytes retrieval, and numbers of mature or fertilized oocytes. The r-hFSH+r-hLH group attained better clinical outcomes with a lower total dose of gonadotropin than the r-hFSH+hMG group while no significant difference in the rate of OHSS was present. The cLBR was significantly higher in the r-hFSH+r-hLH group, which agreed to the results of pregnancy rates in previous similar studies (14, 15). A meta-analysis regarding multiple combinations of gonadotropins on ART also indicated the highest pregnancy rate in the group administering r-hFSH with r-hLH than hMG or FSH alone (19). The results of the present study implied that LH activity from purified or recombinant sources could lead to discrepant outcomes in COH. The efficacy of r-hLH may be more consistent than hMG when used to stimulate LH receptors, as Dahan et al. suggested (14). Besides, it was reported that LH and hCG evoked different cellular and molecular responses, albeit acting on the same receptor (i.e., luteinizing hormone-chorionic gonadotropin receptor [LHCGR]) (22). Since the LH activity in hMG was mainly from its hCG component, which has a longer half-life in the human body than LH and shares only ~85% identity with LH (23), it is not surprising that the two regimens led to significantly different results.

Aside from the outcomes generally investigated by other studies, we particularly analyzed the cycles of the first ET (both fresh ET and FET) regarding that the best embryos were chosen at the first ET attempt. Moreover, from the patients’ points of view, getting pregnant at the first ET shortened the duration of treatment. In terms of the parameters before the embryo transfer procedure, the patterns of the outcomes in the first ET cycles were comparable to those in total cycles, with better clinical outcomes including the numbers of retrieved, mature, and fertilized oocytes in the r-hFSH+r-hLH group. Fewer embryos were transferred with a significantly lower miscarriage rate in the group of r-hFSH+r-hLH. There was also a consistent trend of higher implantation rate, pregnancy rate, and live birth rate in the r-hFSH+r-hLH group, although not significantly different. Giving the live birth rate differed by 6.5% (Group 1 vs. Group 2, 38.7% vs. 45.2%), the small sample size may have played a role in the lack of statistical significance. In conclusion, r-hFSH+r-hLH showed more positive outcomes than r-hFSH+hMG in the analysis of either total cycles or the first ET cycles.

The lower total FSH and LH dose in the r-hFSH+r-hLH group than the r-hFSH+hMG group is consistent with the data in previous investigations with similar study groups (14, 16). The patients benefit from not only less exposure to medications but also from fewer burdens of injection treatment.

**TABLE 3 Outcomes of 1st ET cycles.**

| Stimulation cycle | GROUP 1. r-hFSH + hMG | GROUP 2. r-hFSH+ r-hLH | P-value |
|-------------------|-----------------------|------------------------|---------|
| n=256             | n=166                 |                        |         |
| E2 level on the trigger day (pg/ml) | 2633.41 ± 1711.69 | 3079.41 ± 2313.80 | 0.036*  |
| Endometrial thickness (mm) | 11.29 ± 2.80   | 11.18 ± 2.57     | 0.665   |
| No. of oocytes retrieved | 12.54 ± 8.81       | 14.64 ± 9.53     | 0.021*  |
| No. of mature oocytes | 9.38 ± 6.86       | 11.87 ± 7.89     | <0.001* |
| No. of fertilized oocytes | 9.21 ± 7.14       | 10.82 ± 7.88     | 0.031*  |
| No. of Grade 1-2 embryos on Day 3 | 3.12 ± 3.36    | 3.47 ± 3.44      | 0.302   |
| No. of embryos transferred | 2.11 ± 0.75     | 1.95 ± 0.80      | 0.030*  |
| No. of successful implantation | 0.71 ± 0.77  | 0.70 ± 0.76      | 0.896   |
| Implantation rate | 39 ± 44%         | 43 ± 46%         | 0.370   |
| Pregnancy rate | 134 (52.34%) | 88 (53.01%) | 0.893   |
| Live birth rate | 99 (38.67%) | 75 (45.18%) | 0.185   |
| Miscarriage rate | 35 (26.12%) | 13 (14.77%) | 0.045*  |
| Moderate or severe OHSS | 4 (1.56%) | 3 (1.81%) | 0.848   |

*Statistical significance. Values are presented in mean ± standard deviation or number (percentage).
phenomenon was not observed in the study conducted by Gómez-Palomares et al., in which only women over 38 years old were recruited (15). However, in the study of Bühler and Fischer, the significantly lower dose of the r-hFSH+r-hLH group was seen in both subgroups of over and under 35 years old (16). As a result, more information is needed to identify whether the discrepancy among the literature in gonadotropin dose was due to age or other factors.

The research on the efficacy of hMG versus FSH in COH has been abundant (19). Nonetheless, during retrospective data collection, we found that hMG or r-hFSH was seldomly used alone in the hospital except for women with distinct baseline characteristics. The group of r-hFSH alone were relatively younger (mean age = 33.72) and had a higher AMH level (mean = 6.91 ng/ml), whereas the group of hMG alone tended to be older (mean age = 39.27) with a lower AMH level (mean = 1.11 ng/ml). Consequently, this study focused on the r-hFSH+hMG and r-hFSH+r-hLH groups for analysis. The two combinations were frequently seen in real-world practice according to the clinical data and were hence meaningful to help provide insights in determining a suitable regimen for COH. To our knowledge, this study is the first to compare hMG and r-hLH when supplemented to r-hFSH during COH with GnRH-antagonist protocol on Eastern Asians. Previous studies comparing r-hFSH+hMG and r-hFSH+r-hLH were mainly conducted on Western populations, and most of them applied GnRH-agonist protocol for pituitary gland downregulation (14–16). There have been few studies in Asian countries, and the design of their research groups differs from the present study (24, 25).

**FIGURE 2**

The cumulative live birth rate in Group 1 (r-hFSH+hMG) and Group 2 (r-hFSH+r-hLH). *represents statistical significance (p<0.05).
While most baseline parameters between the study groups were similar, the basal LH level and the trigger types were statistically different in this study. A previous study suggested no significant correlation between the basal LH level and IVF outcomes (26). Higher basal LH levels were reported to be associated with better ART outcomes in another study, and the LH levels were 3.4 ± 0.7 mIU/mL and 7.2 ± 2.8 mIU/mL in the literature (27). In our study, the values were much closer. The basal LH level of Group 1 was 3.88 ± 2.06 mIU/mL in total cycles and 3.93 ± 2.03 mIU/mL in the first ET cycles, and the number was 4.58 ± 4.19 mIU/mL and 4.72 ± 4.42 mIU/mL in Group 2, respectively. All these mean values of the basal LH levels were within the reference range. The difference in LH levels between the two groups was therefore considered acceptable. Concerning the trigger types, a recent meta-analysis that included both the GnRH agonist and the dual trigger versus the hCG found no significant difference in pregnancy rate (28). The number of oocytes retrieved was reported to be significantly higher with the dual trigger than hCG alone. Given that the vast majority applied the dual trigger and only a small proportion applied hCG alone in our study, we suggest that the trigger type would not be a critical factor affecting the results when comparing hMG and r-hLH.

The study was limited by its retrospective nature. Additionally, this study utilized propensity score matching to reduce the bias caused by demographic factors or baseline characteristics, which may result in some limitations to the analysis. First, the basal LH level and the trigger types were statistically different as mentioned above. Secondly, the matching method produced an average population for

**TABLE 4 Outcomes of 1st fresh ET cycles.**

| Stimulation cycle                  | GROUP 1. r-hFSH + hMG | GROUP 2. r-hFSH + r-hLH | P-value |
|-----------------------------------|------------------------|--------------------------|---------|
| E2 level on the trigger day (pg/mL) | 1844.60 ± 1192.00      | 1922.61 ± 1170.59        | 0.660   |
| Endometrial thickness (mm)        | 11.15 ± 2.92           | 11.18 ± 2.73             | 0.945   |
| No. of oocytes retrieved          | 8.94 ± 5.91            | 10.13 ± 6.30             | 0.191   |
| No. of mature oocytes             | 6.80 ± 4.50            | 8.11 ± 5.51              | 0.075   |
| No. of fertilized oocytes         | 6.54 ± 4.56            | 7.34 ± 4.92              | 0.258   |
| No. of Grade 1-2 embryos on Day 3 | 2.31 ± 2.18            | 2.55 ± 2.58              | 0.491   |
| No. of embryos transferred        | 2.20 ± 0.83            | 2.06 ± 0.84              | 0.265   |
| No. of successful implantation    | 0.47 ± 0.63            | 0.54 ± 0.71              | 0.520   |
| Implantation rate                 | 27 ± 39%               | 31 ± 44%                 | 0.470   |
| Pregnancy rate                    | 49 (39.84%)            | 30 (42.25%)              | 0.741   |
| Live birth rate                   | 34 (27.64%)            | 25 (35.21%)              | 0.270   |
| Miscarriage rate                  | 15 (30.61%)            | 5 (16.67%)               | 0.167   |
| Moderate or severe OHSS†          | 1 (0.81%)              | 2 (2.82%)                | 0.276   |

Values are presented in mean ± standard deviation or number (percentage).

**TABLE 5 Outcomes of 1st FET cycles.**

| Stimulation cycle                  | GROUP 1. r-hFSH + hMG | GROUP 2. r-hFSH + r-hLH | P-value |
|-----------------------------------|------------------------|--------------------------|---------|
| E2 level on the trigger day (pg/ml) | 3356.49 ± 1906.57      | 3953.16 ± 2572.19        | 0.058   |
| Endometrial thickness (mm)        | 11.43 ± 2.68           | 11.18 ± 2.46             | 0.466   |
| No. of oocytes retrieved          | 15.87 ± 9.71           | 18.02 ± 10.14            | 0.107   |
| No. of mature oocytes             | 11.76 ± 7.76           | 14.68 ± 8.24             | 0.007*  |
| No. of fertilized oocytes         | 11.68 ± 8.16           | 13.42 ± 8.65             | 0.122   |
| No. of Grade 1-2 embryos on Day 3 | 3.87 ± 4.03            | 4.16 ± 3.83              | 0.590   |
| No. of embryos transferred        | 2.04 ± 0.67            | 1.86 ± 0.77              | 0.069   |
| No. of successful implantation    | 0.94 ± 0.82            | 0.83 ± 0.77              | 0.315   |
| Implantation rate                 | 50 ± 45%               | 52 ± 46%                 | 0.800   |
| Pregnancy rate                    | 85 (63.91%)            | 58 (61.05%)              | 0.660   |
| Live birth rate                   | 65 (48.87%)            | 50 (52.63%)              | 0.576   |
| Miscarriage rate                  | 23 (23.53%)            | 8 (13.79%)               | 0.150   |
| Moderate or severe OHSS†          | 3 (2.26%)              | 1 (1.05%)                | 0.495   |

*Statistical significance. Values are presented in mean ± standard deviation or number (percentage). †The OHSS occurred in previous fresh cycles on the same patient.
analysis, while outliers in age, AMH level, basal follicle count, or other factors were excluded. As many other studies examined patients with poor ovarian reserve, women of higher age, or poor responders, the current study could not achieve the same objectives. Finally, this was a single-center study, which limited the sample size and scope of the analysis. The matching process eliminated a large proportion of cycles in the r-hFSH+r-hMG group, further reducing the sample size from one thousand to around three hundred. The algorithm planned to create sample sizes for Groups 1 and 2 in a 2:1 ratio, but the eventual ratio was closer to 3:2, reflecting the restraint on the sample size. In brief, the matching case-control rather than randomization was the main limitation as a retrospective study.

Collectively, the clinical outcomes of COH with r-hFSH+r-hLH were either equal or superior to those with r-hFSH+hMG both in the total cycles and first ET cycles with no significant difference in the risks of OHSS. The results suggest that when administered GnRH-antagonist protocol in Taiwanese women, the r-hFSH+r-hLH regimen could lead to higher clBR. The finding of the present study adds to the increasing evidence of better clinical outcomes of r-hFSH+r-hLH than r-hFSH+hMG in COH. Future research is needed to corroborate this finding and to contribute to the understanding of COH for ART treatment.

Data availability statement

The raw data supporting the conclusions of this article are available from the corresponding author on reasonable request, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by The Institutional Review Board of Taichung Veterans General Hospital No.1650, Sec.4, Taiwan Boulevard, Taichung City, Taiwan. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

Author contributions

M-JC and Y-CY contributed to conception and design of the study. H-FG, Y-FC, H-FK, J-CC, S-TC, and L-YC were responsible for the acquisition of data and organization of the database. Y-FC analysed the data. M-JC and Y-CY drafted the article. All authors contributed to manuscript revision, read, and approved the submitted version.

Funding

Medical writing assistance was funded by Merck Ltd., an affiliate of Merck Healthcare KGaA, Darmstadt, Germany.

Conflict of interest

The authors declare that this study received funding from Merck Ltd., an affiliate of Merck Healthcare KGaA, Darmstadt, Germany. The funder had the following involvement with the study: writing assistance.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2022.931756/full#supplementary-material

References

1. Xiong Y, Bu Z, Dai W, Zhang M, Bao X, Sun Y. Recombinant luteinizing hormone supplementation in women undergoing in vitro fertilization/intracytoplasmic sperm injection with gonadotropin releasing hormone antagonist protocol: A systematic review and meta-analysis. Reprod Biol Endocrinol (2014) 12(1):109. doi: 10.1186/s12958-014-0109-2

2. Alviggi C, Conforti A, Esteves SC, Andersen CY, Bosch E, Bühler K, et al. Recombinant luteinizing hormone supplementation in assisted reproductive technology: A systematic review. Fertil Steril (2018) 109(4):644–64. doi: 10.1016/j.fertnstert.2018.01.003

3. Levi-Setti PE, Zerbetto I, Baggiani A, Zannoni E, Sacchi L, Smeraldi A, et al. An observational retrospective cohort trial on 4,828 IVF cycles evaluating different low prognosis patients following the poseidon criteria. Front Endocrinol (Lausanne) (2019) 10. doi: 10.3389/fendo.2019.00282

4. Conforti A, Esteves SC, Di Bella F, Strina I, De Rosa P, Fiorenza A, et al. The role of recombinant LH in women with hypo-response to controlled ovarian stimulation: A systematic review and meta-analysis. Reprod Biol Endocrinol (2019) 17(1):31. doi: 10.1186/s12958-019-0460-4

5. Arvis P, Massin N, Lehert P. Effect of recombinant LH supplementation on cumulative live birth rate compared with FSH alone in poor ovarian responders: A large, real-world study. Reprod BioMed Online (2021) 42(3):546–54. doi: 10.1016/j.rbmo.2020.08.035
6. Van de Weijer BHM, Mulders JWMM, Boo ES, Verhaert PDEM, Van den Hooven HW. Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menopausal extract). *Reprod BioMed Online* (2003) 7(5):547–57. doi: 10.1016/S1472-6483(10)62071-8

7. Jen BC, Sah CS, Kim YB, Kim SH, Moon SY. Clinical efficacy of highly purified hMG versus recombinant FSH in IVF/ICSI cycle: A meta-analysis. *Gynecol Obstet Invest* (2010) 70(2):132–7. doi: 10.1159/000308458

8. Van Wely M, Kwan I, Burt AL, Thomas J, Vail A, van der Veen F, et al. Recombinant versus urinary gonadotropin for ovarian stimulation in assisted reproductive technology cycles. *Cochrane Database Syst Rev* (2011) (2):CD005354. doi: 10.1002/14651858.CD005354.pub2

9. Revelli A, Pettaianus G, Basso G, Carosso A, Ferrero A, Dallan C, et al. Controlled ovarian stimulation with recombinant FSH plus recombinant LH versus urinary hCG supplementation during controlled ovarian stimulation in women with normal ovarian reserve: Results from a routine clinical practice in a real-life population. *Reprod Biol Endocrinol* (2015) 13(1):1–8. doi: 10.1186/s12995-015-0080-6

10. Moro F, Scarchi E, Palla C, Romani F, Familiari A, Tropea A, et al. Highly purified hMG versus recombinant FSH plus recombinant LH in intrauterine insemination cycles in women ≥35 years: A RCT. *Hum Reprod* (2015) 30(1):179–85. doi: 10.1093/humrep/deu302

11. Pacchiarotti A, Sbracia M, Frega A, Selman H, Rinaldi L, Pacchiarotti A. Urinary hMG (Menopur) versus recombinant FSH versus recombinant LH (Pergoveris) in IVF: A multicenter, prospective, randomized controlled trial. *Fertil Steril* (2010) 94(6):2467–9. doi: 10.1016/j.fertnstert.2010.04.035

12. Carone D, Caropreso C, Vitti A, Chiappetta R. Efficacy of different gonadotropin combinations to support ovulation induction in WHO type I anovulation infertility: Clinical evidence of human recombinant FSH/human recombinant LH in a 2:1 ratio and highly purified human menopausal gonadotropin stimula. *J Endocrinol Invest* (2012) 35(11):996–1002. doi: 10.3275/8657

13. Mignini Renzini M, Brigante C, Cotichico G, Dal Canto M, Caliari I, Comi R, et al. Retrospective analysis of treatments with recombinant FSH and recombinant LH versus human menopausal gonadotropin in women with reduced ovarian reserve. *J Assist Reprod Genet* (2017) 34(12):1645–51. doi: 10.1007/s10815-017-1034-z

14. Dahan MH, Agdi M, Shehata F, Son W, Tan SL. A comparison of outcomes from *in vitro* fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropin, in subjects with good or poor ovarian reserve: A retrospective analysis. *Eur J Obstet Gynecol Reprod Biol* (2014) 172(1):70–3. doi: 10.1016/j.ejogrb.2013.10.027

15. Gómez-Palomares JL, Acredo-Martín B, Andrés L, Ricciaroli E, Hernández ER. LH improves early follicular recruitment in women over 38 years old. *Reprod BioMed Online* (2005) 11(4):409–14. doi: 10.1016/S1472-6483(10)61131-5

16. Bühler KF, Fischer R. Recombinant human LH supplementation versus supplementation with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol: A matched case-control study. *Gynecol Endocrinol* (2012) 28(5):345–50. doi: 10.3109/09513390.2011.633128

17. Wang R, Lin S, Wang Y, Qian W, Zhou L. Comparisons of GnRH antagonist protocol versus GnRH agonist long protocol in patients with normal ovarian reserve: A systematic review and meta-analysis. *PloS One* (2017) 12(4):1–19. doi: 10.1371/journal.pone.0175985

18. Al-Inany HG, Youssef MA, Ayelleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. *Cochrane Database Syst Rev* (2016) 4:CD001750. doi: 10.1002/14651858.CD001750.pub4

19. Santi D, Casarini L, Alviggi C, Simonì M. Efficacy of follicle-stimulating hormone (FSH) alone, FSH + luteinizing hormone, human menopausal gonadotropin or FSH + human chorionic gonadotropin on assisted reproductive technology outcomes in the “personalized” medicine era: A meta-analysis. *Front Endocrinol* (Lausanne) (2017) 8. doi: 10.3389/fendo.2017.00114

20. Veek L. An atlas of human gametes and conceptuses: An illustrated reference for assisted reproductive technology. New York, USA: Parthenon Publishing, (1999) p. 46–51.

21. Chang J-C, Chen M-J, Guo H-F, Chen Y-F, Yi Y-C, Kung H-F, et al. Does the “freeze-all” policy allow for a better outcome in assisted reproductive techniques than the use of fresh embryo transfers? – A retrospective study on cumulative live birth rates. *Taiwan J Obstet Gynecol* (2017) 56(6):775–80. doi: 10.1016/j.tjog.2017.10.013

22. Casarini L, Lisi P, Longobardi S, Milosa F, La Marca A, Tagliasacchi D, et al. LH and hCG action on the same receptor results in qualitatively and quantitatively different intracellular signalling. *Placenta* (2012) 33(9):e468–e472. doi: 10.1016/j.placenta.2012.06.002

23. Casarini L, Santi D, Brigante G, Simonì M. Two hormones for one receptor: Evolution, biochemistry, actions, and pathophysiology of LH and hCG. *Endocr Rev* (2018) 39(5):549–92. doi: 10.1210/er.2018-00065

24. Vuong TNL, Phung HT, Ho MT. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: A randomized controlled trial. *Hum Reprod* (2015) 30(5):1188–95. doi: 10.1093/humrep/dev038

25. Mak SMJ, Wong WY, Chung HS, Chung PW, Li TC, Kong GWS, et al. Effect of mid-follicular phase recombinant LH versus urinary hCG supplementation in poor ovarian responders undergoing IVF – A prospective double-blinded randomized study. *Reprod BioMed Online* (2017) 34(3):258–66. doi: 10.1016/j.rbmo.2016.11.014

26. Prasad S, Gupta T, Divya A. Correlation of the day 3 FSH/LH ratio and LH concentration in predicting IVF outcome. *J Reprod Infertil* (2013) 14(1):23–8.

27. Tolgoz VY, Tekin AB. High basal LH levels are associated with improved cycle outcomes of assisted reproduction. *J Surg Med* (2020) 4(2):152–6. doi: 10.29892/jsm.666963

28. Zhang Y, Guo X, Guo L, Chang HM, Shu J, Leung PKC. Outcomes comparison of IVF/ICSI among different trigger methods for final oocyte maturatation: A systematic review and meta-analysis. *FASEB J* (2021) 35(7):1–12. doi: 10.1096/fj.2021004056R